BenevolentAI SPAC Presentation Deck

Broad IP Portfolio and High quality peer-reviewed publications • We protect both our drug pipeline and our technology platform, using patents, copyright and trade secrets. • We use IP rights to retain our competitive advantages and, where appropriate, publish our scientific and technology research in order to improve the lives of patients and retain leadership in the field. THE LANCET Baricitinib as potential treatment for 2019-nCoV acute respiratory disease (2020) Identified a novel antiviral mechanism from public data using Knowledge Graph and tools in just 48 hours - most effective treatment for COVID-19 shown in RCTs. nature Rosalind: Preclinical validation of therapeutic targets predicted by tensor factorization on heterogeneous graphs (2020) "Time-slicing" experiment showing we can predict future therapeutic targets and clinical trial successes beyond other state of the art approaches. 200 JCIM JOURNAL OF CHEMICAL INFORMATION AND MODELING Deeply Tough: Learning Structural Comparison of Protein Binding Sites (2020) Convolutional neural network designed to structurally compare protein binding sites - - to help guide hit-finding, polypharmacology, and characterization of protein function. Comprehensive tech and drug patent portfolios ✔ 55 drug patent applications across 7 programmes ✓ 71 tech patent applications covering all four key tech areas ✔ 20+ peer reviewed papers published Benevolent 18

View entire presentation